{"id":10770,"date":"2018-03-22T11:19:06","date_gmt":"2018-03-22T11:19:06","guid":{"rendered":"http:\/\/www.lihnnhs.info\/Sando\/?p=10770"},"modified":"2018-03-22T11:46:23","modified_gmt":"2018-03-22T11:46:23","slug":"knowledge-lert-for-thursday-22nd-march","status":"publish","type":"post","link":"https:\/\/www.lihnnhs.info\/Sando\/2018\/03\/22\/knowledge-lert-for-thursday-22nd-march\/","title":{"rendered":"Knowledge @lert for Thursday 22nd March"},"content":{"rendered":"
\n

Sophie Black,\u00a0senior practice development midwife at Ormskirk Hospital has a paper published in the\u00a0British Journal Of Midwifery\u00a0<\/strong>
\nBlack, S E. 2018,<\/a> Obstetric emergencies: Enhancing the multidisciplinary team through simulation,\u00a0<\/a><\/em>British Journal Of Midwifery, 26, 2, pp. 96-102<\/a>\u00a0(Login with your NHS Open Athens account)
\nHigh fidelity simulation plays a major role in training and assessing the competence of staff. Staff valued the simulation and reported that they achieved increased confidence and communication skills as a result of participating.<\/p>\n

\n

Sepsis Manual – Sepsis Trust UK<\/strong>
\nThe new Sepsis Manual <\/a>is now available to download<\/p>\n

\n

Pressure ulcers: productivity calculator –\u00a0NHS Improvement<\/strong>
\nTool <\/a>to help NHS organisations and commissioners understand the productivity and cost elements associated with treating pressure ulcers<\/p>\n

\n

Brexit: medicines and medical devices<\/strong>
\nThe Health Select Committee has published Brexit: medicines, medical devices and substances of human origin<\/a>.\u00a0 The Committee is urging UK and EU negotiators to prioritise patient safety in the next round of Brexit negotiations.<\/p>\n

\n

General Medical Services contract<\/strong>
\nNHS England has announced agreement of the 2018\/19 GP contract<\/a>.\u00a0 The new contract will take effect from 1 April 2018 and will see an investment of \u00a3256.3 million in the contract for 2018\/19, a 3.4% increase overall.\u00a0 Other actions agreed include complete roll out of the Electronic Prescription Service, funding to support full implementation of the e-Referral Service, and widening the pilot of NHS 111 directly booking GP appointments.<\/p>\n

\n

The Government\u2019s mandate to NHS England for 2018-19 –\u00a0Department of Health and Social Care<\/strong>
\nThe government\u2019s mandate to NHS England <\/a>sets its objectives and budget, and helps to ensure that the NHS is accountable to Parliament and the public. Building on the multi-year approach taken to setting the mandate since 2016, it continues to set objectives and goals to 2020, as well as some specific things that NHS England should be seeking to deliver in the financial year 2018 to 2019.<\/p>\n

\n

NICE guidance<\/strong><\/h3>\n

NICE guideline <\/strong><\/p>\n\n\n\n
NG89<\/td>\nVenous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Medical technologies guidance<\/strong><\/p>\n\n\n\n
MTG37<\/td>\nThopaz+ portable digital system for managing chest drains<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Technology appraisal guidance<\/strong><\/p>\n\n\n\n\n\n\n
TA511<\/td>\nBrodalumab for treating moderate to severe plaque psoriasis<\/a><\/td>\n<\/tr>\n
TA512<\/td>\nTivozanib for treating advanced renal cell carcinoma<\/a><\/td>\n<\/tr>\n
TA513<\/td>\nObinutuzumab for untreated advanced follicular lymphoma<\/a><\/td>\n<\/tr>\n
TA514<\/td>\nRegorafenib for previously treated advanced hepatocellular carcinoma<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Quality Standard (updated)<\/strong><\/p>\n\n\n\n
QS3<\/td>\nVenous thromboembolism in adults: reducing the risk in hospital<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
\n

Statistics<\/strong><\/p>\n